Michael Grissinger

Insider Reports History

Location
Boston, MA
Signature
/s/ John Hamill, as Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Michael Grissinger:

Company Role Class Num Shares Value Price $ Report Date Ownership
Aprea Therapeutics, Inc. Director Common Stock 2,889 $4,680 $1.62 05 Jun 2025 Direct
Akari Therapeutics Plc Director Ordinary Shares, par value $0.0001 per share 20,000,000 01 Jan 2024 Direct
Akari Therapeutics Plc Director Stock Option (Right to Buy) 5,000,000 28 Jun 2024 Direct
Adicet Bio, Inc. Director Stock Option (Right to Buy) 70,200 17 Apr 2025 Direct
Aprea Therapeutics, Inc. Director Stock Options (Right to Buy) 4,185 20 Jun 2024 Direct
Aprea Therapeutics, Inc. Director Stock Options (Right to Buy) 4,185 05 Jun 2025 Direct

Insider Reports Filed by Michael Grissinger

Symbol Company Period Transactions Value $ Form Type Role Filing Time
APRE Aprea Therapeutics, Inc. 05 Jun 2025 2 $0 4 Director 09 Jun 2025, 16:03
ACET Adicet Bio, Inc. 17 Apr 2025 1 $0 4 Director 21 Apr 2025, 16:11
ACET Adicet Bio, Inc. 17 Apr 2025 0 $0 3 Director 21 Apr 2025, 16:09
AKTX Akari Therapeutics Plc 28 Jun 2024 1 $0 4 Director 02 Jul 2024, 16:30
APRE Aprea Therapeutics, Inc. 20 Jun 2024 2 $0 4 Director 21 Jun 2024, 16:16
AKTX Akari Therapeutics Plc 01 Jan 2024 0 $0 3 Director 02 Jan 2024, 18:41
APRE Aprea Therapeutics, Inc. 23 Aug 2023 2 $0 4 Director 24 Aug 2023, 21:51
APRE Aprea Therapeutics, Inc. 28 Jul 2022 2 $0 4 Director 01 Aug 2022, 17:02
APRE Aprea Therapeutics, Inc. 16 May 2022 0 $0 3 Director 26 May 2022, 16:15